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Background: Cardiovascular disease (CVD) results from a combination of abnormalities in lipoprotein metabolism,
oxidative stress, chronic inflammation, and susceptibility to thrombosis. Atherosclerosis is the major cause of CVD.
CD36 has been shown to play a critical role in the development of atherosclerotic lesions by its capacity to bind
and promote endocytosis of oxidized low-density lipoprotein (oxLDL) and is implicated in the formation of foam
cells. The purpose of this research was to evaluate whether there is an association of sCD36 and oxLDL levels with
cardiovascular risk factors in young subjects.
Methods: A total of 188 subjects, 18 to 25 years old, 133 normal-weight and 55 obese subjects from the state of
Guerrero, Mexico were recruited in the study. The lipid profile and glucose levels were measured by enzymatic
colorimetric assays. Enzyme-linked immunosorbant assays (ELISA) for oxLDL and sCD36 were performed. Statistical
analyses of data were performed with Wilcoxon- Mann Whitney and chi-square tests as well as with multinomial
regression.
Results: TC, LDL-C, TG, oxLDL and sCD36 levels were higher in obese subjects than in normal-weight controls, as
well as, monocyte and platelet counts (P < 0.05). Obese subjects had 5.8 times higher risk of sCD36 in the third tertil
(>97.8 ng/mL) than normal-weight controls (P = 0.014), and 7.4 times higher risk of oxLDL levels in third tertile
(>48 U/L) than control group. The subjects with hypercholesterolemia, hypertriglyceridemia, fasting impaired LDL-C
had a higher risk of oxLDL levels in the third tertile (>48 U/L) than the control group (P < 0.05).
Conclusions: Circulating CD36 and oxLDL levels are associated with cardiovascular risk factors in young subjects
and may be potential early markers for cardiovascular disease (CVD).
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Cardiovascular disease (CVD) risk factors such as ad-
vanced age, obesity, smoking, hyperlipidemia, diabetes,
and hypertension, account for 30–40% of the worldwide
prevalence of this disease [1]. The pathological basis of
CVD results from a combination of abnormalities in lipo-
protein metabolism, oxidative stress, chronic inflamma-
tion, and susceptibility to thrombosis [2]. Atherosclerosis
is the major cause of CVD [3], it is considered a chronic
inflammatory disease of the arterial wall that underlies
many of the common causes of cardiovascular morbidity* Correspondence: iprojas@yahoo.com
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article, unless otherwise stated.and mortality, including myocardial infarction (MI), cere-
brovascular and peripheral vascular disease [4].
A key process in the pathogenesis of atherosclerosis is
the deposition of cholesterol in the arterial wall. Lipo-
proteins are involved in this process, including choles-
terol carried by very low-density (VLDL), remnant
lipoproteins and low-density lipoproteins (LDL), particu-
larly the small and dense forms; conversely, cholesterol
is carried away from the arterial wall by high-density
lipoprotein (HDL) [5].
Oxidative modification of LDL (oxLDL) in the arter-
ial wall is central to the pathogenesis of atherosclerosis
[6]. OxLDL is associated with carotid intimal-media
thickness, unstable plaques in the coronary and carotid
arteries, impaired brachial and coronary endothelialCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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loses its ability to bind to LDL receptors, this interferes
with its normal processing and as a result gains affinity
for a family of proteins called scavenger receptors [8].
This leads to macrophage activation, foam-cell forma-
tion, secretion of growth factors and proinflammatory
cytokines, thereby promoting plaque formation [9,10].
CD36, an 88 kDa glycoprotein, was originally described
as platelet receptor glycoprotein which belongs to the class
B scavenger receptor family [11,12]. CD36 is expressed on
an extensive range of cells and tissues, including micro-
vascular endothelial cells, monocytes and macrophages,
dendritic cells, adipocytes, keratinocytes, cardiac and ske-
letal muscle, retinal pigment epithelium, microglia, reticulo-
cytes, breast, gut, renal epithelium, platelets, hepatocytes,
smooth muscle cells and binds to a diverse array of ligands
[13-16]. CD36 is best characterized as a free fatty acid
transporter involved in different biological processes like
angiogenesis, inflammation, lipid metabolism, atheroscler-
osis and platelet activation [17].
Monocyte/macrophage CD36 has been shown to play
a critical role in the development of atherosclerotic le-
sions by its capacity to bind and promote endocytosis of
oxLDL, and is also implicated in the formation of foam
cells [18,19]. Moreover, the pathogenic role of oxLDL in
atherosclerosis largely depends on CD36 [20].
A soluble form of CD36 (sCD36), a marker of altered
tissue CD36 expression, was recently identified in hu-
man plasma, and elevated levels were found in obesity
and type 2 diabetes. In this regard, sCD36 in plasma has
been reported up to 4-fold higher in obese T2D-patients
compared to lean healthy control subjects [21]. The cir-
culating concentration of CD36 is also associated with
markers of liver injury in subjects with altered glucose
tolerance [22]. A recent study revealed that soluble
CD36 in plasma correlates significantly with markers of
atherosclerosis, insulin resistance and fatty liver in a
non-diabetic healthy population [23]. Due to the wide-
spread tissue expression of CD36 and its broad range of
functions it is difficult to foresee which specific patho-
logical processes may reflect alterations in sCD36 [24].
However, a recent study showed that sCD36 is not a
proteolytic product, but it is associated with a specific
subset of circulating microparticles (MPs) that can read-
ily be analyzed and which originate mainly from platelets
in normal subjects [25]. In this regard, the aim of this re-
search was to evaluate whether there is an association of




A total of 188 subjects were randomly selected, 18 to
25 years old, 133 normal-weight controls (BMI 18.5 to24.9 kg/m2) and 55 obese subjects (BMI ≥30 kg/m2)
from the state of Guerrero, Mexico. There were 117
women and 71 men; participants were not under any
medication or had evidence of metabolic disease other
than obesity. All subjects gave their written informed
consent previous explanation of the purpose and nature
of the study. The protocol was approved by the Research
Ethics Committee of the University of Guerrero.
Blood pressure
Blood pressure was measured in the sitting position with
the use of an automatic sphygmomanometer on the left
arm after 10 min rest. The systolic blood pressure (SBP)
and diastolic blood pressure (DBP) were calculated from
two readings with a minimal interval of 10 min. Hyper-
tension was defined as mean SBP ≥140 mmHg and/or
DBP ≥90 mmHg [26].
Biochemical analysis
A venous blood sample of 5 mL was obtained from each
subject after at least a 12 hours fasting. All serum lipid
levels and glucose were determined by enzymatic methods
with commercially available kits (Spinreact). Abnormal bio-
chemical levels were identified when total-cholesterol
(TC) ≥ 200 mg/dL, triglycerides (TG) ≥ 150 mg/dL, low-
density lipoprotein cholesterol (LDL-C) > 100 mg/dL, high-
density lipoprotein cholesterol (HDL-C) < 40 mg/dL and
glucose >100 mg/dL, based on the criteria of the National
Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Chol-
esterol in Adults (Adult Treatment Panel III) [27].
Determination of sCD36 and oxLDL levels
Enzyme-linked immunosorbant assays (ELISA) for oxLDL
(Mercodia Oxidized LDL ELISA) and sCD36 (Human sol-
uble CD36 ELISA, kit-Aviscera Bioscience) were performed,
according to the manufacturer’s instructions, with an
intra-assay CV <6% and interassay CV <7% for oxLDL
ELISA assay, and an intra-assay CV <5% and interassay
CV <9% for CD36 ELISA assay.
Statistical analysis
The statistical analyses were performed with the statis-
tical software package SPSS 15.0 and STATA software
9.0. Quantitative variables were expressed as medians
and 25th to 75th percentiles and significant differences
between groups were determined using the Wilcoxon-
Mann Whitney test. Qualitative variables were expressed
as percentages and the differences between groups were
determined using the chi-square test. The association
analysis between serum levels of oxLDL and sCD36 with
lipid phenotypes was carried out with multinomial re-
gression, where a P value <0.05 was considered statisti-
cally significant.
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General and biochemical characteristics
General and biochemical characteristics of the study
subjects are shown in Table 1. Measurements of body
weight, height, systolic and diastolic blood pressure,
prevalence of hypertension, and TC, LDL-C, TG, sCD36
and oxLDL levels were higher in obese subjects than in
normal-weight controls, as well as, the monocyte and
platelet counts (P < 0.05). There were no significant dif-
ferences by gender (P = 0.162).
Correlations between sCD36 and oxLDL levels with
selected variables
In all subjects studied, sCD36 correlated significantly
with weight, BMI, waist, hip, waist-to-hip ratio,% fat,%
fat mass, LDL-C, oxLDL and monocyte count. Obese
subjects showed a high correlation among BMI and
sCD36 (r = 0.50, P = 0.028) (Table 2). The oxLDL levels
correlated positively with weight, BMI, waist, hip, waist-Table 1 Anthropometric and biochemical variables by
group
Variables Normal weight Obesity P value
n 133 55 -
Age (years) 20 (19-22) 21 (20-23) 0.005
Gender 0.162
Female (%) 87 (65) 30 (55)
Male (%) 46 (35) 25 (45)
Weight (kg) 54.5 (49.2-59.4) 90.9 (79.1-99.9) 0.001
Height (cm) 158.7 (153.0-167.5) 163.5 (155-171) 0.036
BMI (kg/m2) 21.5 (20.0-23.4) 33.1 (31.3-35.3) 0.001
SBP (mmHg) 104 (98-112) 115 (112-121) 0.001
DBP (mmHg) 68 (61-73) 70 (67-77) 0.003
Hypertension 0.001
No 124 (93.9) 35 (67.3)
Yes 8 (6.1) 17 (32.7)
TC (mg/dL) 152 (136-173) 160 (137-195) 0.057
HDL-C (mg/dL) 43 (38-54) 44 (38-47) 0.717
LDL-C (mg/dL) 89 (61-116) 117 (88-157) 0.001
TG (mg/dL) 72 (56-98) 121 (75-89) <0.001
Glucose (mg/dL) 83 (75-89) 83 (77-90) 0.386
Monocytes (%) 7 (5-9) 9 (7-11) 0.0005
Platelets (103/mm3) 247 (215-289) 265 (232-307) 0.048
sCD36 (ng/mL) 32.3 (16.8-102.4) 146.3 (76.7-694.7) 0.002
oxLDL (U/L) 35.4 (27.9-47.1) 51.5 (38.0-59.7) <0.001
BMI, Body Mass Index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure;
TC, Total Cholesterol; HDL-C, High-Density Lipoprotein Cholesterol; LDL-C,
Low-Density Lipoprotein Cholesterol; TG,Triglyceride; oxLDL, oxidized Low-
Density Lipoprotein. Values were presented as median (percentile 25-75th).
Difference between genders was determined by the Wilcoxon-Mann–Whitney
test. Hypertension data were presented in (n) and percentages; the difference
between genders was determined by chi-square test.to-hip ratio,% fat,% fat mass, and TC, TG, LDL-C, sCD36
and monocyte count in all subjects. In normal-weight and
obese groups, oxLDL levels showed a high correlation
with weight, BMI, waist, waist-to-hip ratio,% fat mass, and
TG, LDL-C levels and monocyte count (Table 3).
Circulating CD36 and oxLDL levels according to metabolic
abnormalities
Subjects with hypertriglyceridemia and hypertension had
higher levels of sCD36, while oxLDL levels were higher in
subjects with hypercholesterolemia, hypertriglyceridemia,
LDL-C and hypertension compared to those subjects with-
out these abnormalities (P < 0.05) (Table 4).
Association of cardiovascular risk factors with sCD36 and
oxLDL levels
For the association analysis with cardiovascular risk factors,
sCD36 was classified into tertiles (first tertile <23.3 ng/mL,
second tertile 23.3 to 97.8 ng/mL and third tertile >97.8 ng/
mL), since there are no established reference values. Obese
subjects had 5.8 times higher risk of sCD36 in the third
tertile than normal-weight controls, adjusted for age and
gender (P = 0.014) (Table 5). The oxLDL levels were also
classified into tertiles (first tertile <31.9 U/L, second tertile
31.9 to 48.0 U/L and third tertile >48.0 U/L) in order to
analyze their association with cardiovascular risk factors.
Table 5 shows that subjects with hypercholesterolemia
had 7.5 times higher risk of oxLDL levels in the third ter-
tile than subjects without these abnormalities. IndividualsTable 2 Correlation between sCD36 and selected
variables
Variables All subjects Normal weight Obesity
r p r p r p
Weight (kg) 0.29 0.004 0.14 0.217 0.41 0.073
Height (cm) 0.03 0.774 0.04 0.724 0.15 0.534
BMI (kg/m2) 0.32 0.001 0.17 0.150 0.50 0.028
Waist (cm) 0.30 0.003 0.13 0.2474 0.30 0.210
Hip (cm) 0.31 0.002 0.18 0.1190 0.30 0.201
Waist-to-hip ratio 0.23 0.026 0.001 0.988 0.02 0.931
% Fat 0.32 0.001 0.19 0.097 −0.02 0.909
% Fat mass 0.35 0.0006 0.22 0.058 0.30 0.203
Glucose (mg/dL) −0.15 0.132 −0.16 0.168 −0.01 0.954
TC (mg/dL) −0.05 0.609 −0.15 0.201 0.16 0.479
TG (mg/dL) 0.15 0.134 −0.001 0.991 0.33 0.151
HDL-C (mg/dL) 0.07 0.456 0.10 0.373 −0.06 0.771
LDL-C (mg/dL) 0.21 0.038 0.02 0.803 0.23 0.325
oxLDL (U/L) 0.25 0.024 0.06 0.623 0.29 0.334
Monocytes (%) 0.33 0.001 0.22 0.056 0.20 0.376
Platelets (103/mm3) 0.15 0.142 0.03 0.741 0.23 0.309
r = Spearman correlation coefficient; p = p value.
Table 3 Correlation between oxLDL levels and selected
variables
Variables All subjects Normal weight Obesity
r p r p r p
Weight (kg) 0.43 0.0001 0.23 0.009 0.31 0.026
Height (cm) 0.05 0.438 −0.06 0.499 0.17 0.234
BMI (kg/m2) 0.51 0.0001 0.40 <0.001 0.37 0.009
Waist (cm) 0.52 0.0001 0.39 <0.001 0.38 0.007
Hip (cm) 0.36 0.0001 0.10 0.225 0.21 0.139
Waist-to-hip ratio 0.53 0.0001 0.42 <0.001 0.30 0.034
% Fat 0.32 0.0001 0.13 0.124 0.09 0.516
% Fat mass 0.41 0.0001 0.21 0.014 0.39 0.005
Glucose (mg/dL) −0.10 0.182 −0.19 0.027 0.12 0.398
TC (mg/dL) 0.32 <0.001 0.17 0.053 0.67 <0.001
TG (mg/dL) 0.47 <0.001 0.38 <0.001 0.33 0.018
HDL-C (mg/dL) 0.04 0.557 0.04 0.621 0.11 0.422
LDL-C (mg/dL) 0.43 <0.001 0.33 0.0001 0.53 0.0001
sCD36 (ng/mL) 0.25 0.024 0.06 0.623 0.29 0.334
Monocytes (%) 0.40 <0.001 0.31 0.0003 0.34 0.020
Platelets (103/mm3) 0.01 0.889 0.01 0.879 −0.15 0.293
r = Spearman correlation coefficient; p = p value.
Table 4 sCD36 and oxLDL levels according to metabolic
abnormalities






No (176) 47.7 (18.4-219.9) 37.8 (29.5-50.6)
Yes (12) 62.2 (16.7-200.4) 52.7 (30.1-60.5)
P = 0.93 P = 0.20
Hypercholesterolemia
(≥200 mg/dL)
No (162) 44.9 (17.3-223.6) 36.7 (29.1-48.5)
Yes (26) 74.8 (25.7-98.7) 54.5 (45.5-65.0)
P = 0.55 P = 0.0002
Fasting LDL-C
(>100 mg/dL)
No (95) 47.7 (17.2-208.2) 32.4 (27.8-45.6)
Yes (93) 74.8 (21.8-270.4) 47.1 (35.8-57.1)
P = 0.30 P = 0.0001
Fasting HDL-C
(<40 mg/dL)
No (88) 61.1 (19.6-262) 45.6 (31.9-54.3)
Yes (100) 46.7 (17.9-127.2) 34.6 (29-48.5)
P = 0.49 P = 0.06
Hypertriglyceridemia
(≥150 mg/dL)
No (161) 43.1 (16.7-190.6) 36.1 (28.2-48.1)
Yes (27) 180.3 (66.01-2295) 52.5 (48.5-59.7)
P = 0.01 P = 0.0001
Hypertension
(SBP ≥140 mmHg, DBP≥ 90 mmHg)
No (161) 34.1 (16.7-190.6) 37.6 (29–119.0)
Yes (27) 79.8 (66.01-200.4) 48.0 (31.5-58.8)
P = 0.03 P = 0.1218
The values were presented as median (percentile 25-75th). The difference
between genders was determined by the Wilcoxon-Mann–Whitney test.
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oxLDL levels in the third tertile and subjects with hypertri-
glyceridemia had 17.9 times higher risk of oxLDL levels in
the third tertile, adjusted for age, gender and BMI. Likewise,
obese individuals had 7.4 times higher risk of oxLDL levels
in third tertile than controls, adjusted for age and gender.
Discussion
In this research, we found a higher prevalence of hyper-
tension in obese subjects (32.7%) than in normal weight
subjects (6.1%), with a prevalence of 13.6% in the total
study subjects. These findings are similar to those re-
ported in another study in U.S. teenagers; where hyper-
tension showed a prevalence of 30% in obese subjects
[28]. It is known that the increase sodium reabsorption
induced by angiotensin II produced by adipocytes affects
renal natriuresis, so that obese subjects need higher
blood pressure levels than normal weight subjects to
maintain a balance between the sodium intake and
renal diuresis [29].
In this study, as in previous studies the lipid profile
(TC, LDL-C and TG) was higher in obese subjects than
normal-weight controls. This may be due to increased
adiposity since adipose tissue undergoes morphological
and physiological changes which include the release of
proinflammatory cytokines such as tumour necrosis fac-
tor alpha (TNF-α), and in turn, decrease insulin sensitiv-
ity and increase lipolysis. These morphological changes
contribute to insulin resistance and dyslipidemia [30].An interesting finding in this study was that obese sub-
jects have a higher number of monocytes and platelets
than the normal-weight subjects. The leukocyte count is
considered as an indicator of inflammatory status in obes-
ity [31]. In addition, research has shown that adults and
children with obesity have higher levels of leukocytes,
mainly monocytes, compared with adults and children of
normal weight [32-34]. Regarding increased platelet count
in subjects with obesity, similar findings have been shown
in other studies, where the platelet count is higher in teen-
agers and adults with obesity than normal weight subjects
[35,36]. In relation to cytokines, it has been shown that
interleukin-6 (IL-6) induces differentiation of megakar-
yocytes into platelets and that IL-6 is produced by adi-
pose tissue [37,38]. Furthermore, it has been reported
Table 5 Association of cardiovascular risk factors with sCD36 and oxLDL levels
Variables sCD36 levels (>97.8 ng/mL) oxLDL levels (>48 U/L)
OR (95% CI) R2 p value OR (95% CI) R2 p value
Hypercholesterolemia 0.9 (0.14-5.75) 0.098 0.932* 7.5 (1.80-31.15) 0.155 0.006*
Impaired fasting LDL-C 0.7 (0.22-2.45) 0.085 0.622* 4.5 (1.79-11.31) 0.152 0.001*
Impaired fasting HDL-C 0.4 (0.15-1.46) 0.103 0.195* 0.3 (0.10-0.63) 0.147 0.003*
Hypertriglyceridemia 5.3 (0.50-55.87 0.094 0.164* 17.9 (2.03-158.92) 0.154 0.009*
Hypertension 4.5 (0.45-44.63) 0.098 0.197* 0.51 (0.13-1.98) 0.117 0.336*
Obesity 5.8 (1.43-24.05) 0.070 0.014** 7.4 (2.82-19.60) 0.80 <0.001**
*Adjusted for age, gender and BMI, **Adjusted for age and gender.
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which may explain the increase in platelets in an obese
state.
In this study, we observed that sCD36 was higher in
obese subjects than in normal weight subjects (143.3 ng/
mL vs. 32.3 ng/mL, P = 0.002), these results are congru-
ent with previous studies [21,40]. This may be due to
the increased number of platelets and monocytes shown
in obese subjects, as was recently reported that the cir-
culating form of the CD36 receptor is associated with
microparticles mainly originated of platelets, leukocytes
and endothelial cells as a result of stimuli or apoptosis
[8,25]. These microparticles have been found increased
in subjects with insulin resistance and obese with type 2
diabetes, due to presence of a low-grade inflammation
[41-43]. In this study, we observed that serum oxLDL
levels were higher in obese subjects than in control
group (51.5 U/L vs. 35.4 U/L), these results are consist-
ent with those reported in other studies [44]. This may
be due to the increase oxidative stress in an obese state,
which favors the oxidation of LDL-C [45,46].
We observed a high correlation of sCD36 with BMI in
obese subjects (r =50, P = 0.028), similar results have been
reported in previous studies [47]. In addition, oxLDL
levels showed a strong correlation with BMI, TG and
LDL-C in subjects with and without obesity. Such correla-
tions are similar to those reported in other studies [48,49].
In this research, sCD36 in the third tertile (>97.8 ng/mL)
were associated with obesity, although there is a lack of
studies that support this association, sCD36 have been
correlated with BMI [47,50]. Higher sCD36 in obese
subjects than in normal weight subjects have also been
reported in other studies [21,43]. Furthermore, it is pro-
posed that high CD36 levels may be a marker of in-
creased CD36 expression known from a number of
tissues that are associated with the metabolic syndrome;
macrophage infiltration and low-grade inflammation in
abdominal obesity, which may lead to dyslipidemia and
peroxidation of lipoproteins [24].
We also found that oxLDL levels in third tertile (>48.0
U/L) were associated with hypercholesterolemia, im-
paired fasting LDL-C, hypertriglyceridemia and obesity.The association between dyslipidemia and oxidation of
LDL has been demonstrated in individuals in the
pre-diabetic state [48]. It has also been observed in mid-
dle-aged people that obesity and dyslipidemia are the
strongest predictors of oxLDL levels [51]. The associ-
ation between cardiovascular disease (CVD) and oxLDL
has been demonstrated in others studies [52-55]. Con-
sidering the associations shown in this study (sCD36
and oxLDL levels with traditional cardiovascular risk
factors such as obesity, hypercholesterolemia, hypertri-
glyceridemia and impaired fasting LDL-C), measuring
sCD36 and oxLDL levels can be incorporated into car-
diovascular risk factors in young subjects for early diag-
nosis of cardiovascular disease.
Our research has some limitations. We could not study
the associations between sCD36 and oxLDL levels with
early atherosclerosis. As our study is comprised of young
subjects without clinical atherosclerotic diseases, we were
only able to study associations between traditional car-
diovascular risk factors with sCD36 and oxLDL levels.
Whether the increase of these markers in young sub-
jects is associated with the silent phase of atheroscler-
osis remains to be elucidated. The authors believe that a
greater obese group is desirable to improve the power of
the study.
Conclusions
In this research, sCD36 and oxLDL levels are associated
with cardiovascular risk factors, particularly with obesity,
hypercholesterolemia, impaired fasting LDL-C and
HDL-C and hypertriglyceridemia. Therefore, sCD36 and
oxLDL levels may be potential early markers for CVD.
However, these associations should be investigated in
further studies.
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